ANIX - Anixa Biosciences, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ANIX

ANIXA BIOSCIENCES, INC.

NASDAQ

$2.90

▼ DOWN 0.34% (-0.01)

KEY STATISTICS

Market Cap$98.67 M

52w High$5.46

52w Low$2.32

Dividend Yield—

Frequency—

P/E-9.35

Volume217.78K

Shares Out.34.02M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Amit Kumar

COMPENSATION 2026

Salary$815,170

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$102,414

Total$2,546,684

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 7, 1983

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

PRICE TARGET

Target High$6.00

Target Low$6.00

Target Median$6.00

Target Consensus$6.00

UPCOMING EARNINGS

DateJan 11, 2027

DayMonday

Rev. Est.—

JAN

MON

SPLIT RECORD

DATE	TYPE	RATIO
2015-06-26	Reverse	1:25
1996-06-18	Forward	2:1
1991-03-19	Forward	2:1
1987-09-16	Forward	5:4
1985-11-12	Forward	3:1

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

13.40%

HOLDERS

101

TOP 8 OF 101 · RANKED BY POSITION SIZE

Laird Norton Trust Company, LLC

Geode Capital Management, LLC

364.7K sh

$941.44K

Mission Wealth Management, LP

Susquehanna International Group, Llp

252.1K sh

$786.47K

PRICE

$2.90 ▼ DOWN 0.34% (−$0.01)

OVERLAYS

About Anixa Biosciences, Inc.

https://www.anixa.com ↗

Anixa Biosciences develops innovative therapies and vaccines for oncology and infectious diseases, including CAR-T treatments, anti-viral drugs for COVID-19, and vaccines targeting breast and ovarian cancers.

INDUSTRY

Biotechnology

A PRODUCT ANIXA BIOSCIENCES, INC. IS KNOWN FOR

Liraltagene Autoleucel (lira-cel)

Anixa's CAR-T therapy for recurrent ovarian cancer, in Phase 1 trials, shows promising survival results and recent regulatory approval for dose escalation, forming a key part of its therapeutic pipeline.

COMPETITORS

COMPETITOR

Anixa Biosciences in 2025

SENTIMENT: + POSITIVE

INNOVATION · DECEMBER 2025

Anixa Biosciences Unveils Positive Phase 1 Data for Investigational Breast Cancer Vaccine, Sparking Significant Investor Interest

Anixa Biosciences announced positive final data from the Phase 1 clinical trial of its investigational breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. The study, conducted in collaboration with Cleveland Clinic, met all primary endpoints, demonstrating the vaccine was safe and generated an immune response in 74% of participants, setting the stage for a Phase 2 trial.

PRODUCT STRATEGY · DECEMBER 2025 · IN PROGRESS

Anixa Biosciences Takes Full Control of its Breast Cancer Vaccine Program to Advance into Phase 2 Clinical Trials

In a pivotal strategic move, Anixa Biosciences assumed full sponsorship of the Investigational New Drug (IND) application for its breast cancer vaccine from the Cleveland Clinic. This decision followed the announcement of positive final data from the Phase 1 trial, positioning Anixa to independently lead the next crucial stage of clinical development.

Latest News

PRNEWSWIRE · OCT 5, 2026

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment.

READ ARTICLE

EARLIER COVERAGE

PRNEWSWIRE · OCT 1, 2026

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.

READ ARTICLE